Lantern Pharma (LTRN) Assets Average (2020 - 2026)

Lantern Pharma (LTRN) has reported Assets Average for 7 consecutive years, with $7.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average fell 58.91% year-over-year to $7.9 million; the trailing twelve-month figure through Jun 2026 stood at $7.9 million (down 58.91% YoY), and the FY2025 full-year result was $18.3 million, down 47.11% from the prior year.
• Assets Average retreated to $7.9 million in Q2 2026 per LTRN's latest filing, from $9.1 million in the prior quarter.
• Across five years, Assets Average topped out at $71.2 million in Q1 2022 and bottomed at $7.9 million in Q2 2026.
• Historically, Assets Average has averaged $38.7 million across 5 years, with a median of $39.7 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Assets Average surged 38.39% in 2022, then slumped 60.88% in 2026.
• Over 5 years, Assets Average stood at $60.5 million in 2022, then fell by 24.45% to $45.7 million in 2023, then tumbled by 38.89% to $27.9 million in 2024, then slumped by 55.85% to $12.3 million in 2025, then sank by 35.83% to $7.9 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $7.9 million, $9.1 million, and $12.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.